Synthesis and Biophysical Evaluation of 2 - American Chemical Society

Feb 8, 2010 - §Current address: Regulus Therapeutics,. 1896 Rutherford Road, Carlsbad, CA 92008. [email protected]. Received December 2, 2009...
0 downloads 0 Views 1MB Size
Download PDF
pubs.acs.org/joc

Synthesis and Biophysical Evaluation of 20 ,40 -Constrained 20 O-Methoxyethyl and 20 ,40 -Constrained 20 O-Ethyl Nucleic Acid Analogues Punit P. Seth,*,† Guillermo Vasquez,† Charles A. Allerson,† Andres Berdeja,‡ Hans Gaus,‡ Garth A. Kinberger,† Thazha P. Prakash,† Michael T. Migawa,† Balkrishen Bhat,§ and Eric E. Swayze† †

Department of Medicinal Chemistry and ‡Department of Structural Biology, Isis Pharmaceuticals, 1896 Rutherford Road, Carlsbad, California 92008. §Current address: Regulus Therapeutics, 1896 Rutherford Road, Carlsbad, CA 92008. [email protected] Received December 2, 2009

We have recently shown that combining the structural elements of 20 O-methoxyethyl (MOE) and locked nucleic acid (LNA) nucleosides yielded a series of nucleoside modifications (cMOE, 20 ,40 -constrained MOE; cEt, 20 ,40 -constrained ethyl) that display improved potency over MOE and an improved therapeutic index relative to that of LNA antisense oligonucleotides. In this report we present details regarding the synthesis of the cMOE and cEt nucleoside phosphoramidites and the biophysical evaluation of oligonucleotides containing these nucleoside modifications. The synthesis of the cMOE and cEt nucleoside phosphoramidites was efficiently accomplished starting from inexpensive commercially available diacetone allofuranose. The synthesis features the use of a seldom used 2-naphthylmethyl protecting group that provides crystalline intermediates during the synthesis and can be cleanly deprotected under mild conditions. The synthesis was greatly facilitated by the crystallinity of a key mono-TBDPS-protected diol intermediate. In the case of the cEt nucleosides, the introduction of the methyl group in either configuration was accomplished in a stereoselective manner. Ring closure of the 20 -hydroxyl group onto a secondary mesylate leaving group with clean inversion of stereochemistry was achieved under surprisingly mild conditions. For the S-cEt modification, the synthesis of all four (thymine, 5-methylcytosine, adenine, and guanine) nucleobase-modified phosphoramidites was accomplished on a multigram scale. Biophysical evaluation of the cMOE- and cEt-containing oligonucleotides revealed that they possess hybridization and mismatch discrimination attributes similar to those of LNA but greatly improved resistance to exonuclease digestion.

Introduction Antisense drug discovery technology represents a powerful method to modulate gene expression in animals.1 The most advanced oligonucleotides in the clinic are second (1) Antisense Drug Technology: Principles, Strategies, and Applications, 2nd ed.; Crooke, S. T., Ed.; CRC Press: Boca Raton, 2007.

DOI: 10.1021/jo902560f r 2010 American Chemical Society

Published on Web 02/08/2010

generation antisense oligonucleotides (ASOs), which typically have a central DNA region of 8-14 nucleotides, flanked on the 50 and 30 ends with five to two 20 -O-methoxyethyl (MOE, 2) residues.2 The above “gapmer” design (2) Monia, B. P.; Lesnik, E. A.; Gonzalez, C.; Lima, W. F.; McGee, D.; Guinosso, C. J.; Kawasaki, A. M.; Cook, P. D.; Freier, S. M. J. Biol. Chem. 1993, 268, 14514–14522.

J. Org. Chem. 2010, 75, 1569–1581

1569

JOC Article

Seth et al.

FIGURE 2. Structures of LNA and other related conformationally

restricted 20 -40 bridged nucleic acids (BNA) reported in the literature.

FIGURE 1. Design of constrained methoxyethyl (R-cMOE 5 and S-cMOE 6) and constrained ethyl (R-cEt 7 and S-cEt 8) nucleic acids.

supports RNase H mediated degradation of target mRNA due to the central DNA region. At the same time, the flanking MOE residues increase hybridization to complementary mRNA and further stabilize the oligonucleotide toward enzymatic degradation. There are currently almost 20 second generation ASOs in human clinical trials for a variety of disease indications including hypercholesteremia, diabetes, and cancer. We have shown that replacing MOE nucleosides in second generation ASOs with locked nucleic acid (LNA) 4 increases the potency of some ASOs in animals. However, this was sometimes accompanied with an increased risk for hepatotoxicity.3 We hypothesized that replacing LNA with novel nucleoside monomers that combine the structural elements of MOE and LNA might mitigate the toxicity of LNA while maintaining potency. To this end we designed and prepared nucleoside analogues 5 (R-constrained MOE, R-cMOE) and 6 (S-constrained MOE, S-cMOE), 7 (R-constrained ethyl, RcEt), and 8 (S-constrained ethyl, S-cEt) where the 20 O-alkyl group was constrained back to the 40 position of the furanose ring (Figure 1).4 The 20 -40 constraint enforces a N-type sugar pucker of the furanose ring and thereby improves hybridization with complementary RNA.5 Biological evaluation of the cMOE and cEt containing ASOs showed that the S-cEt-modified ASOs displayed activity comparable to that of LNA with no elevations in liver transaminase levels after 3 weeks of dosing.6 Thus small structural changes on the LNA scaffold appear to have a significant impact on the biological profile of oligonucleotides containing these modifications. It is conceivable that further structure activity relationship studies on (3) Swayze, E. E.; Siwkowski, A. M.; Wancewicz, E. V.; Migawa, M. T.; Wyrzykiewicz, T. K.; Hung, G.; Monia, B. P.; Bennett, C. F. Nucleic Acids Res. 2007, 35, 687–700. (4) Seth, P. P.; Siwkowski, A.; Allerson, C. R.; Vasquez, G.; Lee, S.; Prakash, T. P.; Kinberger, G.; Migawa, M. T.; Gaus, H.; Bhat, B.; Swayze, E. E. Nucleic Acids Symp. Ser. 2008, 553–554. (5) Wengel, J. Acc. Chem. Res. 1999, 32, 301–310. (6) Seth, P. P.; Siwkowski, A.; Allerson, C. R.; Vasquez, G.; Lee, S.; Prakash, T. P.; Wancewicz, E. V.; Witchell, D.; Swayze, E. E. J. Med. Chem. 2009, 52, 10–13.

1570

J. Org. Chem. Vol. 75, No. 5, 2010

the LNA scaffold will provide additional modifications that have a superior biological profile as compared to that of LNA. As such, since the first report of LNA by Imanishi7-9 and by Wengel,10-14 a number of analogues have been reported in the literature (Figure 2). Some of the analogues contain subtle structural changes such as replacing the 20 oxygen atom with nitrogen or sulfur to provide 20 -thio LNA 1015 and 20 -amino LNA 9,16,17 respectively. Other analogues differ based on the size and composition of the 20 -40 bridging substituent. Examples of such analogues include ENA 11,18 aza ENA 12,19 carbo ENA 13,20,21 14,22 PrNA 15,18 BNACOC 1623 and BNANC 17.24,25 Recently, (7) Obika, S.; Nanbu, D.; Hari, Y.; Morio, K.-I.; In, Y.; Ishida, T.; Imanishi, T. Tetrahedron Lett. 1997, 38, 8735–8738. (8) Obika, S.; Nanbu, D.; Hari, Y.; Andoh, J.-I.; Morio, K.-I.; Doi, T.; Imanishi, T. Tetrahedron Lett. 1998, 39, 5401–5404. (9) Imanishi, T.; Obika, S. J. Synth. Org. Chem. Jpn. 1999, 57, 969–980. (10) Singh, S. K.; Nielsen, P.; Koshkin, A. A.; Wengel, J. Chem. Commun. 1998, 455–456. (11) Koshkin, A. A.; Singh, S. K.; Nielsen, P.; Rajwanshi, V. K.; Kumar, R.; Meldgaard, M.; Olsen, C. E.; Wengel, J. Tetrahedron 1998, 54, 3607– 3630. (12) Singh, S. K.; Wengel, J. Chem. Commun. 1998, 1247–1248. (13) Koshkin, A. A.; Rajwanshi, V. K.; Wengel, J. Tetrahedron Lett. 1998, 39, 4381–4384. (14) Koshkin, A. A.; Nielsen, P.; Meldgaard, M.; Rajwanshi, V. K.; Singh, S. K.; Wengel, J. J. Am. Chem. Soc. 1998, 120, 13252–13253. (15) Kumar, R.; Singh, S. K.; Koshkin, A. A.; Rajwanshi, V. K.; Meldgaard, M.; Wengel, J. Bioorg. Med. Chem. Lett. 1998, 8, 2219–2222. (16) Singh, S. K.; Kumar, R.; Wengel, J. J. Org. Chem. 1998, 63, 6078– 6079. (17) Singh, S. K.; Kumar, R.; Wengel, J. J. Org. Chem. 1998, 63, 10035– 10039. (18) Morita, K.; Takagi, M.; Hasegawa, C.; Kaneko, M.; Tsutsumi, S.; Sone, J.; Ishikawa, T.; Imanishi, T.; Koizumi, M. Bioorg. Med. Chem. 2003, 11, 2211–2226. (19) Varghese, O. P.; Barman, J.; Pathmasiri, W.; Plashkevych, O.; Honcharenko, D.; Chattopadhyaya, J. J. Am. Chem. Soc. 2006, 128, 15173–87. (20) Albk, N.; Petersen, M.; Nielsen, P. J. Org. Chem. 2006, 71, 7731– 7740. (21) Kumar, S.; Hansen, M. H.; Albk, N.; Steffansen, S. I.; Petersen, M.; Nielsen, P. J. Org. Chem. 2009, 74, 6756–6769. (22) Wang, G.; Gunic, E.; Girardet, J.-L.; Stoisavljevic, V. Bioorg. Med. Chem. Lett. 1999, 9, 1147–1150. (23) Hari, Y.; Obika, S.; Ohnishi, R.; Eguchi, K.; Osaki, T.; Ohishi, H.; Imanishi, T. Bioorg. Med. Chem. 2006, 14, 1029–1038. (24) Miyashita, K.; Rahman, S. M.; Seki, S.; Obika, S.; Imanishi, T. Chem. Commun. 2007, 3765–3767. (25) AbdurRahman, S. M.; Seki, S.; Obika, S.; Yoshikawa, H.; Miyashita, K.; Imanishi, T. J. Am. Chem. Soc. 2008, 130, 4886–4896.

JOC Article

Seth et al. SCHEME 1.

Problems with 30 O-Bn Protecting Group Strategy

FIGURE 3. Retrosynthetic analysis for cMOE and cEt nucleic acids.

Chattopadhyaya reported the synthesis of substituted carbocyclic LNA and ENA analogues 18 via an intramolecular radical cyclization approach,26-28 while Nielsen29 and we30 reported the synthesis of a (R)-6-hydroxymethyl-substituted LNA analogue 19. With the exception of thio-LNA 10 and BNANC 17, all other analogues reduce thermal stability for complementary nucleic acids relative to LNA. A majority of the analogues reported thus far are also significantly more difficult to synthesize, especially in quantities required to carry out meaningful animal experiments, as compared to LNA. In this report, we describe the detailed synthesis and biophysical characterization of the cMOE- and cEt-modified oligonucleotides. We show that these modifications exhibit similar thermal stability and mismatch discrimination but increased nuclease stability as compared to those of LNA. We also describe a new orthogonal protecting group strategy that greatly facilitates the synthesis of this class of molecules and should find general application for the synthesis of other LNA analogues. Results and Discussion The general strategy used to prepare LNA typically involves a cycloetherification reaction between the 20 -hydroxyl and an appropriate leaving group at the 40 position of the nucleoside furanose ring system.7,11,13,31 For our purpose, we decided to implement a similar strategy to prepare the cMOE and cEt analogues (Figure 3). However, to the best of our knowledge, there were no reports that described the stereoselective cyclization of the 20 -hydroxyl onto a secondary leaving group required to generate the 6-substituted-2,5dioxa-bicyclo[2.2.1]heptane ring system present in the (26) Srivastava, P.; Barman, J.; Pathmasiri, W.; Plashkevych, O.; Wenska, M.; Chattopadhyaya, J. J. Am. Chem. Soc. 2007, 129, 8362–8379. (27) Zhou, C.; Liu, Y.; Andaloussi, M.; Badgujar, N.; Plashkevych, O.; Chattopadhyaya, J. J. Org. Chem. 2009, 74, 118–134. (28) Xu, J.; Liu, Y.; Dupouy, C.; Chattopadhyaya, J. J. Org. Chem. 2009, 74, 6534–6554. (29) Enderlin, G.; Nielsen, P. J. Org. Chem. 2008, 73, 6891–6894. (30) Seth, P. P.; Swayze, E. E. U.S. Patent 7399845, 2008. (31) Koshkin, A. A.; Fensholdt, J.; Pfundheller, H. M.; Lomholt, C. J. Org. Chem. 2001, 66, 8504–8512.

cMOE and cEt nucleoside analogues. Access to diastereomerically pure cMOE and cEt nucleoside analogues hinged upon identifying methods to prepare nucleoside 21 in a stereodefined manner. We envisaged a strategy where secondary alcohol 22 could be prepared from aldehyde 23 by the stereoselective addition of an appropriate organometallic reagent. The overall topology of the sugar in 23 and the presence of a neighboring co-ordination site were expected to provide the appropriate elements of stereocontrol during addition of the organometallic reagent. Lastly, it was crucial to identify a robust protecting group strategy that could differentiate the two primary alcohols in 24 on a multigram scale. At first we chose to differentiate the two primary hydroxyls in diol 25 using the benzyl protecting group strategy that has been utilized for the synthesis of LNA and related molecules in the literature7,11 (Scheme 1). However, separation of the desired benzyl intermediate 26 from its regioisomers was found to be cumbersome, especially on a large scale. Nonetheless, we were able to elaborate diol 25 to the cyclized nucleoside intermediate 27.30 However, removal of the 30 O-benzyl protecting group in 27 proved to be difficult and irreproducible. Use of Pd/C under mild reaction conditions resulted in very slow and erratic removal of the benzyl group and often required multiple catalyst changes to drive the reaction to completion. Use of more forcing conditions (ammonium formate, palladium hydroxide) resulted in partial hydrogenolysis of the uridine nucleobase, which could not be easily separated from the desired product 28.32 Use of boron trichloride resulted in the formation of significant amounts of the anhydro nucleoside 29.30 Presumably, presence of the methyl substituent in 27 results in increased ring strain, which in turn activates the cyclic ether to cleave under strong Lewis acid conditions. To circumvent the problems associated with removal of the 30 O-benzyl group, we decided to replace the benzyl group with a 2-naphthylmethyl (abbrev. naphthyl or Nap) protecting group, which possesses similar acid stability as a benzyl group but can be cleaved under mild (32) Kumar, S. T.; Kumar, P.; Sharma, P. K.; Hrdlicka, P. J. Tetrahedron Lett. 2008, 49, 7168–7170.

J. Org. Chem. Vol. 75, No. 5, 2010

1571

JOC Article SCHEME 2. Synthesis of Key Mono-TBDPS Diol 32 from Diacetone Allofuranose

oxidative conditions using 2,3-dichloro-4,5-dicyano quinone (DDQ)33 or by hydrogenolysis.34 Synthesis of the cMOE and cEt nucleosides commenced with protecting the 30 -hydroxyl of commercially available diacetone allofuranose with 2-bromomethyl naphthalene to provide 30 O-naphthyl diacetone allofuranose 30 (Scheme 2). The use of the naphthyl protecting group yielded immediate dividends as, unlike 30 O-benzyl-protected diacetone allofuranose, 30 could be cleanly precipitated from the reaction mixture in essentially quantitative yield. Selective cleavage of the 5,6-acetonide with aqueous acetic acid, followed by oxidative cleavage of the resulting diol with sodium periodate and subsequent aldol/Cannizzaro reaction35 provided diol 31 in excellent yield (66% over 3 steps). Once again, the naphthyl protecting strategy proved advantageous as the diol 31 was cleanly isolated from the reaction mixture by precipitation. The next step in the synthesis involved selective protection of the diol 31. Exploratory reactions using tert-butyldimethylsilyl protection provided a mixture of the mono- and di-TBS-substituted sugars, which could be separated by chromatography. In contrast, use of the TBDPS protecting group provided only a mixture of the two mono-protected sugars 32 (60%) and 33 (20%). No di-TBDPS-protected sugar was formed under the reaction conditions employed, presumably due to the increased steric bulk of the TBDPS group. This proved to be extremely beneficial as it permitted using excess TBDPSCl to drive the reaction to completion. Another unexpected outcome of the TBDPS protecting strategy was that the major and desired product 32 was crystalline (33 is an oil that slowly (33) Xia, J.; Abbas, S. A.; Locke, R. D.; Piskorz, C. F.; Alderfer, J. L.; Matta, K. L. Tetrahedron Lett. 2000, 41, 169–173. (34) Gaunt, M. J.; Yu, J.; Spencer, J. B. J. Org. Chem. 1998, 63, 4172– 4173. (35) Youssefyeh, R. D.; Verheyden, J. P. H.; Moffatt, J. G. J. Org. Chem. 1979, 44, 1301–1309. (36) Bhat, B.; Xia, J.; Seth, P. P.; Vasquez, G.; Migawa, M. T.; Allerson, C.; Prakash, T. P.; Swayze, E. E. U.S. Patent 7569686, 2009.

1572

J. Org. Chem. Vol. 75, No. 5, 2010

Seth et al. SCHEME 3. Introduction of Methoxymethyl and Methyl Group for Synthesis of cMOE and cEt Nucleoside Analogues

solidifies upon refrigeration) and could be isolated from the crude mixture by crystallization.36 Armed with a method that allowed for the preparation of the differentiated diol 32 on a kilogram scale, we explored the possibility of introducing the substituent group (methoxymethyl for cMOE and methyl for cEt) in a stereoselective fashion (Scheme 3). Oxidation of the primary alcohol under Swern conditions37 followed by addition of the methoxymethyl magnesium bromide38 provided sugars 34a and 34b as an inseparable mixture. It was very important to control the temperature during the preparation and use of MeOCH2MgBr. This reagent was found to be unstable at temperatures above -20 °C, and the reaction to form the organometallic reagent did not proceed very efficiently at temperatures below -25 °C. Nonetheless, multigram quantities of alcohols 34a,b (95% from 32) could be prepared reproducibly by carefully controlling the reaction conditions for Grignard formation. Even though alcohols 34a,b could not be separated at this stage we decided to move ahead with the hope of separating the mixture at a later stage in the synthesis. For the cEt analogues, addition of MeMgBr in the presence of cerium chloride provided a separable mixture of alcohols 35 and 36 in excellent yield and diastereoselectivity (35:36 ∼10:1). Since we needed access to both methyl stereoisomers, the major alcohol 35 from the Grignard addition was converted to 36 by oxidation to the corresponding ketone followed by reduction with lithium borohydride (36:35 >15:1). The absolute stereochemistry of the alcohols 35 and 36 was not established until after cyclization to the (37) Mancuso, A. J.; Huang, S.-L.; Swern, D. J. Org. Chem. 1978, 43, 2480–2482. (38) Kim, M.; Grzeszczyk, B.; Zamojski, A. Tetrahedron 2000, 56, 9319– 9337.

JOC Article

Seth et al. SCHEME 4.

Synthesis of R- and S-cMOE and R- and S-cEt Uridine Phosphoramidites

R-cEt 41 and S-cEt 42 nucleosides, respectively, assuming a SN2 inversion of the secondary leaving group during the ringclosure reaction. The stereoselectivity observed during addition of the methyl and the hydride group can be explained by means of a chelate-controlled transition state where attack of the nucleophile takes place away from the bulky TBDPS group. The poor stereoselectivity observed during addition of methoxymethylmagnesium bromide could be attributed to the differences in the size, reactivity, and ability to coordinate metal ions for this reagent. Mesylation of the secondary alcohol in sugar intermediates 34a,b, 35, and 36 followed by acetolysis of the 1,2-isopropylidene group provided diacetates 37a,b, 38, and 39, respectively, as an anomeric mixture in good yields (Scheme 4). Installation of the nucleobase in a stereoselective fashion was accomplished by means of a modified Vorbruggen condensation reaction with persilylated uracil.39-41 The nucleoside mixture was not purified at this stage but treated with potassium carbonate in methanol to deprotect the 20 Oacetyl group. To our delight, these conditions resulted in removal of the 20 O-acetyl protecting group as well as cyclization onto the secondary mesylate to provide the cyclized nucleosides 40a,b, 41, and 42, respectively, in excellent yields. Treatment of the mixture of R- and S-cMOE nucleosides 40a,b with DDQ resulted in clean removal of the 30 O-Nap protecting group to provide nucleosides 43a and 43b as a separable mixture. The more polar compound was identified to be the R-cMOE nucleoside 43a, while the less polar spot was the S-cMOE nucleoside 43b. Presumably, the methoxymethyl group in the S-cMOE nucleoside 43b is capable of (39) Vorbr€ uggen, H.; Krolikiewicz, K.; Barbel, B. Chem. Ber. 1981, 114, 1234–1255. (40) Vorbr€ uggen, H.; Barbel, B. Chem. Ber. 1981, 114, 1279–1286. (41) Vorbr€ uggen, H.; Holfe, G. Chem. Ber. 1981, 114, 1256–1268.

FIGURE 4. Structural elucidation of R-cMOE 43a, S-cMOE 43b, R-cEt 44, and S-cEt 45.

forming an intramolecular H-bond with the liberated 30 hydroxyl group, causing this nucleoside to be less polar than the R-cMOE isomer 43a (Figure 4). Deprotection of the 30 ONap group in nucleosides 41 and 42 proceeded smoothly to yield nucleosides 44 and 45, respectively, in high yield. Removal of the 50 O-TBDPS protecting group in nucleosides 43a, 43b, 44, and 45 using buffered triethylamine trihydrofluoride42 provided nucleosides 46-49, respectively. Further protection of the 50 -hydroxyl group with dimethoxytrityl chloride in pyridine provided nucleosides 50-53 in excellent yields (90-99%). A phosphitylation reaction43,44 (42) Bhat, B.; Swayze, E. E.; Wheeler, P.; Dimock, S.; Perbost, M.; Sanghvi, Y. S. J. Org. Chem. 1996, 61, 8186–8199. (43) Sinha, N. D.; Biernat, J.; McManus, J.; Koster, H. Nucleic Acids Res. 1984, 12, 4539–4557. (44) Prakash, T. P.; Johnston, J. F.; Graham, M. J.; Condon, T. P.; Manoharan, M. Nucleic Acids Res. 2004, 32, 828–33.

J. Org. Chem. Vol. 75, No. 5, 2010

1573

JOC Article

Seth et al.

SCHEME 5. Synthesis of Guanine-, Adenine-, and ThymineModified S-cEt Nucleosides

SCHEME 6. Synthesis of Guanine-, Adenine-, and ThymineModified S-cEt Phosphoramidites

of the 50 O-DMT-protected nucleosides provided phosphoramidites 54-57, respectively, in excellent yield after chromatography (83-96%). The stereochemistry of the methoxymethyl group in the cMOE nucleosides 43a and 43b and of the methyl group in the cEt nucleosides 44 and 45 was elucidated by NOESY spectroscopy. For all of the nucleosides, the H10 , H20 , and H30 proton resonances appear as singlets (J ≈ 0 Hz), which is consistent with the sugar pucker being locked in the C30 -endo conformation.7 The stereochemistry of the methoxymethyl groups in 43a and 43b was further confirmed by NOESY spectroscopy where a crosspeak between the H10 and the methylene group of the methoxymethyl substituent was seen for nucleoside 43a and a crosspeak between the H10 and H60 was seen in case of nucleoside 43b. Similarly, a NOESY crosspeak was seen between the axial methyl group and H10 for 44 and between the H60 and H10 for 45. In addition, the structure of the fully deprotected S-cEt uridine nucleoside 49 was unambiguously assigned by X-ray crystallography (Supporting Information). To be able to practice antisense drug discovery with a nucleoside modification in a meaningful manner, it is absolutely essential to have access to multigram quantities of the pyrimidine and purine nucleobase-modified phosphoramidites. Moreover, we also wanted to investigate if the Nap protecting strategy was compatible with the synthesis of purine nucleosides. As a result, we prepared the purine (adenine and guanine) and the 5-methyl pyrimidine (thymine and 5-methyl cytosine) phosphoramidites of the S-cEt modification for further evaluation in antisense drug discovery applications. Synthesis of the purine phosphoramidites was carried out using slight modifications of the procedures previously described for the preparation of LNA purine analogues

(Scheme 5).31 A Vorbruggen reaction of silylated 6-chloro2-aminopurine with diacetate 39 in refluxing dichloroethane provided the nucleoside, which was not purified but treated with the sodium salt of 3-hydroxypropionitrile (20 O-acetate deprotection, ring closure, SNAr displacement of chloro followed by β elimination of acrylonitrile) to provide the cyclized nucleoside 58 in good yield (82% over 2 steps). Protection of the exocyclic amino group as the isobutyryl amide provided nucleoside 59 (71%). Similarly, a Vorbruggen reaction of silylated N-benzoyl adenine with diacetate 39 provided the nucleoside, which was not purified but directly subjected to the cyclization conditions (K2CO3, MeOH) to provide the cyclized product 60 in good yield (73% from 48). Because of partial deprotection of the Nbenzoyl group during the cyclization, the reaction was allowed to continue until the benzoyl group was completely deprotected. The cyclized product 60 was then isolated by crystallization or by silica gel chromatography and reacted with benzoyl chloride to provide the N-benzoyl nucleoside 61 (79%). Synthesis of the thymine-modified S-cEt nucleoside 62 was accomplished using procedures analogous for the preparation of the S-cEt uridine nucleoside 42 (91% over 2 steps). The glycosylation reaction of activated anomeric sugars using silylated purine heterocycles is known to give mixtures of nucleosides arising from reaction at N7 and N9 positions on the purine heterocycle. Typically, the regioisomers equilibrate to the more stable N9 isomer after prolonged heating. Interestingly, during the glycosylation reaction of acetate 39 with 6-chloro-2-aminopurine and N-benzoyl adenine, only a single major N9 isomer was detected after 2 h of reflux in dichloroethane (by LCMS and TLC analysis). Conversion of nucleosides 59, 61, and 62 to the corresponding phosphoramidites 72, 73, and 74 was carried out as shown in Scheme 6. Removal of the 30 O-naphthyl group using DDQ followed by removal of the 50 O-TBDPS protecting group using triethylamine trihydrofluoride yielded nucleosides 66, 67, and 68, respectively, in excellent yield.

1574

J. Org. Chem. Vol. 75, No. 5, 2010

JOC Article

Seth et al. SCHEME 7. Synthesis of 5-Methylcytosine-Modified S-cEt Phosphoramidite

TABLE 1. Thermal Stability Measurements of R- and S-cMOE and Rand S-cEt Modifications with RNA Complement ΔTm sequence Tmb 0 0 a (oC) (oC)/mod. oligomer modification (5 -3 ) A1 A2 A3 A4 A5 A6 A7 A8

Reaction with dimethoxytrityl chloride gave the 50 O-DMTprotected nucleosides 69 (85%), 70 (91%), and 71 (70%), respectively. A phosphitylation reaction provided the phosphoramidites 72 (83%), 73 (95%), and 74 (98%) in excellent yield. Lastly, synthesis of the 5-methyl cytosine S-cEt amidite 76 was accomplished starting from the 50 O-DMT-protected nucleoside 71. In situ transient protection of the 30 -hydroxyl group as the trimethylsilyl ether, followed by triazolation, displacement with aqueous ammonia and protection of the amino group as the benzoyl amide provided nucleoside 75 in good yield (86% over 3 steps).45,46 A phosphitylation reaction provided the desired 5-Me-cytosine-modified S-cEt phosphoramidite 76 (77%) (Scheme 7). Evaluation of cMOE- and cEt-Modified Oligonucleotides in Thermal Denaturation Experiments. All of the nucleoside phosphoramidites were incorporated into oligonucleotides using standard automated phosphoramidite chemistry (Supporting Information). The modified oligomers were evaluated in thermal stability and in nuclease resistance assays. We first evaluated the R- and S-cMOE and R- and S-cEt modifications in an oligonucleotide sequence that has been previously used to measure thermal stability of LNAcontaining oligonucleotides9 (Table 1). In this sequence the R-and S-cMOE and R- and S-cEt oligomers (A2-A5) showed thermal stability similar to that of LNA oligomer A7 (Δ Tm ∼4.5 °C/mod.), indicating that substitution in either configuration at the 6 position of the 2,5-dioxabicyclo ring system is tolerated and does not interfere with hybridization. This observation is important since it suggests that it should be possible to introduce conjugates and/or fluorescent tags by further derivatization of the 6-substituent group,29,30 either in the minor groove or along the edges of the major groove (based on the configuration of the substituent) at site-specific locations within an oligonucleotide without disrupting hybridization. Introduction of the 5-methyl substituent (change from uracil to thymine) on the nucleobase in LNA resulted in a slight increase in thermal stability (þ0.6 °C/mod. A7 vs A8), whereas the effect of the 5-Me substituent on thermal stability was much more pronounced for the S-cEt oligomer A6 (þ1.5 °C/mod. A5 vs A6). (45) Divakar, K. J.; Reese, C. B. J. Chem. Soc., Perkin Trans. 1 1982, 1171–1176. (46) Bhat, V.; Ugarkar, B. G.; Sayeed, V. A.; Grimm, K.; Kosora, N.; Domenico, P. A.; Stocker, E. Nucleosides, Nucleotides Nucleic Acids 1989, 8, 179–183.

DNA R-cMOE S-cMOE R-cEt S-cEt S-cEt LNA LNA

d(GCGTTTTTTGCT) d(GCGTTUTTTGCT) d(GCGTTUTTTGCT) d(GCGTTUTTTGCT) d(GCGTTUTTTGCT) d(GCGTTTTTTGCT) d(GCGTTUTTTGCT) d(GCGTTTTTTGCT)

45.6 50.2 50.4 50.3 50.1 51.7 50.1 50.7

0 þ4.6 þ4.8 þ4.7 þ4.6 þ6.1 þ4.6 þ5.1

a Sequence and composition of ASOs; base code is A = adenine, T = thymine, G = guanine, C = cytosine, U = uracil; upper case letters indicate deoxynucleotide monomers, and bold letters indicate BNA monomers; all internucleosidic linkages are phosphodiester. bTm values were measured in 10 mM sodium phosphate buffer (pH 7.2) containing 100 mM NaCl and 0.1 mM EDTA. Sequence of RNA complement 50 -r(AGCAAAAAACGC)-30 ; each Tm value reflects the average of at least three measurements.

We also examined the ability of oligonucleotides A1-A8 to discriminate between mismatched base pairs using RNA complements with a single base mismatch (Table 2) as reported previously by Imanishi.25 In general, the mismatch discrimination properties of all the modifications evaluated were similar to that observed for the natural DNA/RNA base pairs (A1, -4 °C for T-G, -13 °C for T-C, and -14 °C for T-U mismatched pairs). Oligonucleotides A2-A3 (Rand S-cMOE), A4 and A5 (R- and S-cEt), and A7 (LNA) containing the uracil nucleobase exhibited excellent mismatch discrimination for the U-C (-14 °C) and U-U (-13 °C) mismatched pairs and good mismatch discrimination (-5 to -6 °C) for the U-G mismatch pair. For oligonucleotides A6 (S-cEt) and A8 (LNA) containing the thymine nucleobase, slightly improved mismatch discrimination properties (-6 °C for T-G, -16 °C for T-C, and -14 °C for T-U) were observed. Nuclease Stability of R-cEt, S-cEt, LNA, and MOE Oligonucleotides. Oligonucleotides containing the R- and S-cEt modifications were evaluated in nuclease stability experiments (Figure 5). In one set of experiments, 10-mer poly T DNA oligomers (A09-A13) with two modified residues at the 30 end were digested with snake venom phosphodiesterase (SVPD) (Figure 5). Significant increase in stability toward exonuclease digestion was seen for the R- and ScEt oligonucleotides A12 and A13 as compared to LNA A11, MOE, A10 and DNA A09 oligonucleotides. For both the R-and S-cEt oligonucleotides A12 and A13, >70% intact oligomer was seen after 1290 min. In contrast the MOE (A10) and LNA (A11) oligonucleotides were almost completely degraded at this time point. This result is consistent with recent reports where substitution on the 20 -40 bridging substituent in the BNA scaffold was reported to increase stability of oligonucleotides toward exonuclease digestion.25,26 Conclusion In conclusion, we have shown that the cMOE/cEt modifications exhibit similar thermal stability and mismatch discrimination but increased nuclease stability as compared to those of LNA. The synthesis features the use of a seldom used 2-naphthyl protecting group that provides crystalline intermediates during the synthesis and can be cleanly J. Org. Chem. Vol. 75, No. 5, 2010

1575

JOC Article TABLE 2.

Seth et al.

Mismatch discrimination of DNA, S-cEt and LNA versus mismatched RNA complements Tmb (ΔTm = Tm(mismatch) - Tm(match)) (oC)

oligomer

sequence (50 -30 )a

X = A (match)

G

C

U

A1 (DNA) A2 (R-cMOE) A3 (S-cMOE) A4 (R-cEt) A5 (S-cEt) A6 (S-cEt) A7 (LNA) A8 (LNA)

d(GCGTTTTTTGCT) d(GCGTTUTTTGCT) d(GCGTTUTTTGCT) d(GCGTTUTTTGCT) d(GCGTTUTTTGCT) d(GCGTTTTTTGCT) d(GCGTTUTTTGCT) d(GCGTTTTTTGCT)

45.6 50.2 50.4 50.3 50.1 51.7 50.1 50.7

41.5 (-4.1) 44.0 (-6.2) 44.4 (-6.2) 43.9 (-6.2) 45.6 (-4.5) 45.6 (-5.1) 45.0 (-5.1) 46.0 (-5.7)

32.3 (-13.1) 35.3 (-14.9) 36.1 (-14.3) 35.8 (-14.4) 36.2 (-13.9) 34.1 (-16.1) 35.2 (-14.9) 35.8 (-16.0)

31.8 (-13.8) 37.1 (-13.1) 37.2 (-13.2) 36.3 (-14.0) 36.5 (-13.6) 37.2 (-13.5) 37.2 (-12.9) 37.4 (-14.3)

a Sequence and composition of ASOs; base code is A = adenine, T = thymine, G = guanine, C = cytosine, U = uracil; upper case letters indicate deoxynucleotide monomers, and bold letters indicate BNA monomers; all internucleosidic linkages are phosphodiester. bTm values were measured in 10 mM sodium phosphate buffer (pH 7.2) containing 100 mM NaCl and 0.1 mM EDTA. Sequence of RNA complement 50 -r(AGCAAXAAACGC)-30 .

FIGURE 5. R- and S-cEt-modified oligonucleotides show improved stability to SVPD as compared to LNA, MOE and DNA oligonucleotides. Sequence used for evaluation was TTTTTTTTTTXX; upper case letters denotes deoxynucleotide residues while XX denote modified nucleosides; all internucleosidic linkages are phosphodiester. A09, XX = DNA; A10, XX = MOE T; A11, XX = LNA U; A12, XX = R-cEt U; A13, XX = S-cEt U.

deprotected under mild conditions. The new orthogonal protecting group strategy described in this report will greatly facilitate the synthesis of this class of molecules and should find general application for the synthesis of other LNA analogues. With the exception of LNA, the cMOE/cEt analogues are the only class of BNA modifications where the synthesis of the nucleoside phosphoramidites is scaleable enough to permit meaningful evaluation of these modifications in animal experiments. We are currently evaluating the cMOE and cEt modifications for their ability to modulate gene expression using RNaseH and other antisense mechanisms as well as in diagnostic applications. The results from these experiments will be reported in due course. Experimental Section 4-C-Hydroxymethyl-1,2-O-isopropylidene-3-O-(2-naphthyl)-r(31). Sodium hydride (29.0 g, 727.0 mmol) was added carefully in portions (3-4 g) over 45 min to a cold (0 °C) solution of commercially available 1,2:5,6-di-O-isopropylideneR-D-allofuranose (135.0 g, 519.0 mmol) and 2-bromomethyl naphthalene (126 g, 570 mmol) in DMF (500 mL). After stirring for 1 h, the reaction was very carefully quenched with H2O and then poured onto crushed ice, and the white solid was collected by filtration. The solid was resuspended in a biphasic mixture of water and hexanes (500 mL each), and the suspension was stirred vigorously for 45 min. The solid was collected by filtration and then dried under reduced pressure for 16 h to provide 3-O-(2-naphthyl)-1,2:5,6-di-O-isopropylidene-R-D-allofuranose 30 (206 g, 99%) as a white solid. 1H NMR (300 MHz, CDCl3) D-ribofuranose

1576

J. Org. Chem. Vol. 75, No. 5, 2010

δ: 7.93-7.78 (m, 4 H), 7.60-7.45 (m, 3 H), 5.74 (d, J = 3.6 Hz, 1 H), 4.94 (d, J = 11.9 Hz, 1 H), 4.77 (d, J = 11.9 Hz, 1 H), 4.66-4.54 (m, 1 H), 4.46-4.30 (m, 1 H), 4.24-4.12 (m, 1 H), 4.08-3.88 (m, 3 H), 1.61 (s, 3 H), 1.38 (br s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 135.0, 133.2, 133.2, 128.3, 127.9, 127.7, 127.1, 126.2, 126.1, 126.1, 113.0, 109.7, 103.9, 78.2, 78.0, 77.8, 74.9, 72.4, 65.2, 26.9, 26.7, 26.3, 25.2. ESI-MS m/z: [M þ Na]þ found 423.1, calcd 423.1886. Anal. Calcd for C23H28O6.0.25 H2O: C, 68.21; H, 7.09. Found: C, 68.21; H, 6.92. 30 obtained above was dissolved in glacial acetic acid (2.2 L) and H2O (0.74 L). The reaction was stirred at rt for 16 h after which ∼70% of the solvent was evaporated under reduced pressure on a rotary evaporator. The residue was dissolved in EtOAc (1 L) and the organic layer was washed with water (1 L), saturated sodium bicarbonate, brine, dried (Na2SO4) and concentrated to provide crude 3-O-(2-naphthyl)-1,2-O-isopropylidene-R-D-allofuranose as an oil, which was used without any further purification. 1H NMR (300 MHz, CDCl3) δ: 7.90-7.74 (m, 4 H), 7.55-7.41 (m, 3 H), 5.71 (d, J = 3.4 Hz, 1 H), 4.89 (d, J = 11.5 Hz, 1 H), 4.69 (d, J = 11.5 Hz, 1 H), 4.61-4.48 (m, 1 H), 4.12 (dd, J = 3.1 Hz, 8.8, 1 H), 4.06-3.88 (m, 2 H), 3.68 (br s, 2 H), 2.97 (br s, 1 H), 2.81 (br s, 1 H), 1.60 (s, 3 H), 1.34 (s, 3 H). 13 C NMR (75 MHz, CDCl3) δ: 134.4, 133.2, 128.4, 127.9, 127.7, 127.2, 126.3, 126.2, 126.0, 113.2, 104.2, 79.1, 77.4, 77.3, 77.0, 72.3, 71.1, 63.1, 26.8, 26.6. ESI-MS m/z: [M þ Na]þ found 383.0, calcd 383.1573. A solution of sodium periodate (107 g, 500 mmol) in water (3 L) was added to a solution of the crude diol obtained above in 1,4-dioxane (1.5 L). After stirring at rt for 1 h, the reaction was extracted with EtOAc (1.5 L) and the organic layer was sequentially washed with water, brine, dried (Na2SO4) and concentrated to provide the crude aldehyde (and hydrate) as an oil, which was used without any further purification. Sodium hydroxide solution (2N, 600 mL) was added to a cold (0 °C) solution of crude aldehyde from above and formaldehyde (250 mL, 35% aqueous solution) in THF:H2O (1:1, 1 L) and the mixture was stirred at rt for 72 h. The reaction was extracted with ethyl acetate and the organic layer was washed with water, brine, dried (Na2SO4) and concentrated. After roughly 80% of the solvent was removed (a suspension is formed), hexanes (300 mL) was added to the suspension which was allowed to stand for 16 h at rt. The white solid was collected by filtration and resuspended in a mixture of water and hexanes and stirred vigorously for 2-3 h. The solid was collected by filtration and dried under reduced pressure for 16 h to provide diol 31 (124 g, 66% from 1,2:5,6-Di-O-isopropylidene-R-D-allofuranose) as a white solid. 1H NMR (300 MHz, CDCl3) δ: 7.84 (m, 4 H), 7.50 (m, 3 H), 5.76 (d, J = 3.8 Hz, 1 H), 4.96 (d, J = 11.9 Hz, 1 H), 4.74 (d, J = 11.9 Hz, 1 H), 4.71-4.59 (m, 1 H), 4.26 (d, J = 5.3 Hz, 1 H), 3.96 (br s, 2 H), 3.80 (d, J = 11.9 Hz, 1 H), 3.61 (m, 1 H), 2.40 (m, 1 H), 1.89 (br s, 1 H), 1.66 (s, 3 H), 1.34 (s, 3 H). 13C NMR (75 MHz, CDCl3) δ: 134.7, 133.2, 133.2, 128.5, 127.9,

Seth et al. 127.8, 126.9, 126.4, 126.2, 125.6, 113.6, 104.5, 86.3, 78.5, 78.4, 72.9, 64.3, 63.3, 26.6, 25.9. ESI-MS m/z: [M þ Na]þ found 383.1, calcd 383.1573. Anal. Calcd for C20H24O6: C, 66.65; H, 6.71. Found: C, 66.64; H, 6.62. 5-O-(tert-Butyldiphenylsilyl)-4-C-hydroxymethyl-1,2-O-isopropylidene-3-O-(2-naphthyl)-r-D-ribofuranose (32) and 4-C-(tertButyldiphenylsilyloxymethyl)-1,2-O-isopropylidene-3-O-(2-naphthyl)-R-D-ribofuranose (33). tert-Butyldiphenylsilyl chloride (78.2 mL, 305 mmol) was added to a cold (0 °C) solution of diol 31 (100 g, 278 mmol) and triethylamine (42.8 mL, 305 mmol) in dichloromethane (500 mL). After stirring at rt for 4 d, the reaction was diluted with dichloromethane, sequentially washed with 5% HCl, saturated sodium bicarbonate, and brine, dried (Na2SO4) and concentrated under reduced pressure to provide a thick oil. Hexanes (150 mL) was added to the oil, and the mixture was sonicated to induce crystallization. After standing for 1 h, the white solid was collected by filtration and washed with 5% ether in hexanes to yield diol 32 (100 g total yield; 80 g first crop, 20 g second crop, 60%) as a white solid. Purification of the residual oil by chromatography (silica gel, eluting with 20% to 40% ethyl acetate in hexanes) provided diol 33 (32.5 g, 20%) as a viscous oil. 32: 1H NMR (300 MHz, CDCl3) δ: 7.90-7.26 (m, 17 H), 5.81 (d, J = 3.6 Hz, 1 H), 4.97 (d, J = 11.9 Hz, 1 H), 4.77-4.63 (m, 2 H), 4.48 (d, J = 5.3 Hz, 1 H), 3.96-3.63 (m, 4 H), 2.51-2.35 (m, 1 H), 1.67 (s, 3 H), 1.38 (s, 3 H), 0.92 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 135.6, 135.5, 134.8, 133.2, 133.2, 133.0, 129.7, 129.7, 128.5, 127.9, 127.8, 127.7, 127.7, 126.9, 126.3, 126.2, 125.6, 113.8, 104.5, 87.5, 79.2, 78.0, 72.8, 65.5, 63.3, 27.0, 26.8, 26.3, 19.2. ESI-MS m/z: [M þ Na]þ found 621.1, calcd 621.2751. Anal. Calcd for C36H42O6Si: C, 72.21; H, 7.07. Found: C, 72.17; H, 7.06. 33: 1H NMR (300 MHz, CDCl3) δ: 7.88-7.65 (m, 8 H), 7.52-7.31 (m, 9 H), 5.70 (d, J = 3.8 Hz, 1 H), 4.84 (d, J = 12.2 Hz, 1 H), 4.77 (d, J = 12.1 Hz, 1 H), 4.63-4.51 (m, 1 H), 4.30-4.16 (m, 2 H), 4.16-3.99 (m, 2 H), 3.73-3.57 (m, 1 H), 2.05-1.94 (m, 1 H), 1.25 (br s, 6 H), 1.05 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 135.9, 135.8, 135.2, 133.3, 133.2, 133.1, 129.6, 128.2, 127.9, 127.7, 127.7, 126.8, 126.1, 126.0, 125.8, 113.2, 104.0, 87.3, 78.9, 77.9, 72.7, 65.2, 64.6, 26.9, 26.4, 25.9, 19.3. ESI-MS m/z: [M þ Na]þ found 621.1, calcd 621.2751. Anal. Calcd for C36H42O6Si.0.5 H2O: C, 71.20; H, 7.14. Found: C, 71.21; H, 7.12. 5- O-(tert-Butyldiphenylsilyl)-4-C-(1-hydroxy-2-methoxyethyl)1,2-O-isopropylidene-3-O-(2-naphthyl)-r-D-ribofuranose (34a,b). Dimethylsulfoxide (3.5 mL, 50.0 mmol) was added dropwise to a cold (-78 °C) solution of oxalyl chloride (2.2 mL, 25.0 mmol) in dichloromethane (130 mL). After stirring for 30 min, a solution of diol 32 (12 g, 16.7 mmol) in dichloromethane (30 mL) was added to the reaction. The stirring was continued for 45 min at -78 °C, and triethylamine (10.5 mL, 75.0 mmol) was added to the reaction. The reaction was stirred at -78 °C for 15 min, after which the ice bath was removed and the reaction was allowed to gradually warm over 45 min. The reaction was then poured into CH2Cl2, and the organic phase was sequentially washed with 5% aqueous HCl, saturated NaHCO3, and brine, dried (Na2SO4), and concentrated under reduced pressure to provide the aldehyde, which was used without any further purification. 1H NMR (300 MHz, CDCl3) δ: 9.93 (s, 1 H), 7.94-7.72 (m, 4 H), 7.63-7.26 (m, 13 H), 5.85 (d, J = 3.2 Hz, 1 H), 4.88 (d, J = 12.2, 1 H), 4.81 (d, J = 12.4 Hz, 1 H), 4.72-4.61 (m, 1 H), 4.62-4.52 (m, 1 H), 3.87 (d, J = 11.3 Hz, 1 H), 3.82 (d, J = 11.5 Hz, 1 H), 1.64 (s, 3 H), 1.37 (s, 3 H), 0.92 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 200.2, 135.6, 135.5, 134.5, 133.2, 133.2, 132.8, 132.6, 129.9, 129.8, 128.5, 127.9, 127.8, 127.8, 127.0, 126.3, 126.2, 125.7, 114.2, 105.0, 90.7, 79.1, 78.7, 73.0, 63.2, 26.7, 26.2, 19.2. ESI-MS m/z: [M þ Na]þ found 619.1, calcd 619.2594. A mixture of magnesium turnings (2.5 g, 102.8 mmol) and mercury(II) chloride (93 mg, 0.34 mmol) was covered with dry

JOC Article THF (5 mL), and the reaction was cooled to -20 °C. A few drops of neat methoxymethyl bromide were added to initiate the reaction. After a few minutes, a solution of methoxymethyl bromide (9.33 mL, 102.8 mmol) in THF (12 mL) was added (1 mL every 15 min via a syringe) to the reaction over approximately 3 h. The temperature of the external bath was carefully maintained between -20 and -25 °C during the addition. A small volume of dry THF (5 mL) was added intermittently (over 3 h) to the reaction to facilitate stirring. After the addition of the bromide was complete, the reaction was stirred at -25 °C for 100 min, and a solution of crude aldehyde (from above) in THF (30 mL) was added. After stirring at -20 °C for 45 min, no starting aldehyde was detected by TLC analysis. The reaction was carefully quenched with a solution of saturated ammonium chloride and diluted with ethyl acetate. The organic layer was washed with 5% HCl, a saturated solution of sodium bicarbonate, and brine, dried (Na2SO4), and concentrated to provide alcohols 34a,b (∼1:1). The reaction was repeated a second time using identical conditions as described above with similar results. The crude products from both reactions were combined and purified by chromatography (silica gel, eluting with 15% to 30% ethyl acetate in hexanes) to provide alcohols 34a,b (24.4 g, 95% from 32) as a viscous oil. 1H NMR (300 MHz, CDCl3) δ: 7.90-7.74 (m, 8 H), 7.64-7.44 (m, 14 H), 7.44-7.25 (m, 12 H), 5.95-5.78 (m, 2 H), 5.02 (m, 2 H), 4.75 (m, 2 H), 4.72-4.51 (m, 5 H), 4.36-4.25 (m, 1 H), 3.90 (d, J = 11.3 Hz, 1 H), 3.74 (m, 3 H), 3.62-3.51 (m, 1 H), 3.45 (d, J = 10.9 Hz, 1 H), 3.39-3.20 (m, 4 H), 3.28 (s, 3 H), 3.23 (s, 3 H), 3.13 (s, 1 H), 1.69 (s, 3 H), 1.64 (s, 3 H), 1.39 (s, 6 H), 0.92 (s, 9 H), 0.91 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 135.5, 135.5, 134.7, 134.4, 133.2, 133.1, 133.0, 133.0, 132.8, 132.7, 129.8, 129.7, 129.6, 128.6, 128.4, 127.9, 127.9, 127.7, 127.6, 127.1, 126.8, 126.3, 126.3, 126.2, 126.1, 125.6, 125.6, 114.4, 113.9, 105.0, 104.8, 89.6, 88.0, 79.5, 79.3, 78.1, 78.1, 73.2, 73.0, 72.8, 72.5, 72.3, 70.8, 64.6, 63.5, 59.0, 58.8, 27.0, 26.9, 26.7, 26.6, 19.1, 19.1. ESI-MS m/z: [M þ Na]þ found 665.3, calcd 665.3013. 5-O-(tert-Butyldiphenylsilyl)-4-C-(1S-hydroxyethyl)-1,2-Oisopropylidene-3-O-(2-naphthyl)-r-D-ribofuranose (35) and 5-O(tert-Butyldiphenylsilyl)-4-C-(1R-hydroxyethyl)-1,2-O-isopropylidene-3-O-(2-naphthyl)-R-D-ribofuranose (36). Dimethylsulfoxide (10.8 mL, 152.0 mmol) was added dropwise to a cold (-78 °C) solution of oxalyl chloride (6.7 mL, 76.0 mmol) in dichloromethane (400 mL). After stirring for 30 min, a solution of alcohol 32 (34.2 g, 56.4 mmol) in dichloromethane (40 mL) was added to the reaction. The stirring was continued for 45 min at -78 °C and triethylamine (31.4 mL, 224.0 mmol) was added to the reaction. The reaction was stirred at -78 °C for 15 min, after which the ice bath was removed and the reaction was allowed to gradually warm over 45 min. The reaction was diluted with dichloromethane, and the organic phase was sequentially washed with 5% aqueous HCl, saturated sodium bicarbonate, and brine, dried (Na2SO4), and concentrated to provide the aldehyde, which was used without any further purification. A suspension of cerium(III) chloride (9.2 g, 37.5 mmol) in THF (400 mL) was stirred at rt for 60 min. The reaction was cooled in an ice bath, and methyl magnesium bromide (75.0 mL of a 1.0 M solution in THF) was added over 5 min. After stirring at 0 °C for 90 min, the reaction was cooled to -78 °C, and a solution of crude aldehyde from above in THF (75 mL) was added to the reaction. After 3 h at -78 °C, the reaction was gradually warmed to rt and carefully quenched with saturated ammonium chloride. The reaction was diluted with ethyl acetate, and the organic layer was sequentially washed with 5% HCl, saturated sodium bicarbonate, and brine, dried (Na2SO4), and concentrated. Purification by column chromatography (silica gel, eluting with 10% to 30% ethyl acetate in hexanes) provided pure alcohol 35 (7.4 g, 21% from 32) and a mixture of alcohols 35 and 36 (26.3 g, 76% from 32, 35:36 = 10:1) as viscous oils. J. Org. Chem. Vol. 75, No. 5, 2010

1577

JOC Article 35: 1H NMR (300 MHz, CDCl3) δ: 7.89-7.79 (m, 4 H), 7.65-7.26 (m, 13 H), 5.84 (d, J = 3.6 Hz, 1 H), 5.05 (d, J = 11.5 Hz, 1 H), 4.83-4.53 (m, 4 H), 3.91 (d, J = 11.1 Hz, 1 H), 3.84 (d, J = 11.1 Hz, 1 H), 3.36 (s, 1 H), 1.63 (s, 3 H), 1.39 (s, 3 H), 1.10 (d, J = 6.6 Hz, 3 H), 0.91 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 135.6, 135.5, 134.4, 133.3, 133.3, 133.2, 133.1, 129.7, 129.7, 128.7, 128.0, 127.8, 127.7, 127.7, 127.2, 126.4, 126.3, 125.7, 113.8, 104.8, 88.6, 79.4, 78.3, 73.0, 68.8, 62.4, 27.1, 26.8, 26.7, 19.2, 16.1. HRMS (ESI-FT), Calcd for C37H44O6SiNa, 635.2799; Found 635.2800. ESI-MS m/z: [M þ Na]þ found 635.2. Anal. Calcd for C37H44O6Si.1 H2O: C, 70.44; H, 7.35. Found: C, 70.73; H, 7.11. 36: 1H NMR (300 MHz, CDCl3) δ: 7.88-7.78 (m, 4 H), 7.61-7.27 (m, 13 H), 5.87 (d, J = 3.6 Hz, 1 H), 4.96 (d, J = 12.1 Hz, 1 H), 4.74 (t, 1 H), 4.66 (d, J = 12.1 Hz, 1 H), 4.54 (d, J = 5.3 Hz, 1 H), 4.32-4.18 (m, 1 H), 3.69 (d, J = 10.7 Hz, 1 H), 3.52 (d, J = 10.7 Hz, 1 H), 3.12 (s, 1 H), 1.69 (s, 3 H), 1.39 (s, 3 H), 1.11 (d, J = 6.4 Hz, 3 H), 0.90 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 135.5, 134.8, 133.2, 133.2, 132.9, 132.8, 129.8, 129.7, 128.4, 127.9, 127.7, 126.9, 126.3, 126.1, 125.7, 114.3, 104.5, 90.4, 79.6, 78.1, 72.8, 67.1, 64.6, 26.9, 26.7, 19.1, 17.0. ESI-MS m/z: [M þ Na]þ found 635.2, calcd 635.2907. Anal. Calcd for C37H44O6Si.0.5 H2O: C, 71.46; H, 7.29. Found: C, 71.81; H, 7.55. Preparation of Alcohol 36 Using Lithium Borohydride. Dimethylsulfoxide (37.9 mL, 489.0 mmol) was added dropwise to a cold (-78 °C) solution of oxalyl chloride (21.4 mL, 244.0 mmol) in dichloromethane (800 mL). After stirring for 30 min, a solution of alcohol 35 (100.0 g, 163.0 mmol) in dichloromethane (200 mL) was added to the reaction. The stirring was continued for 45 min at -78 °C, and triethylamine (102.0 mL, 726.0 mmol) was added to the reaction. The reaction was stirred at -78 °C for 15 min, after which the ice bath was removed and the reaction was allowed to gradually warm over 45 min. The reaction was diluted with dichloromethane, and the organic phase was sequentially washed with 10% citric acid solution, saturated sodium bicarbonate, and brine, dried (Na2SO4), and concentrated to provide the crude ketone, which was used without any further purification. 1H NMR (300 MHz, CDCl3) δ: 7.82-7.27 (m, 17 H), 6.06 (d, J = 4.1 Hz, 1 H), 4.88 (d, J = 12.1 Hz, 1 H), 4.82 (d, J = 4.5 Hz, 1 H), 4.66 (d, J = 12.1 Hz, 1 H), 4.24 (d, J = 5.5 Hz, 1 H), 3.89 (d, J = 10.9 Hz, 1 H), 3.70 (d, J = 10.7 Hz, 1 H), 2.38 (s, 3 H), 1.63 (s, 3 H), 1.43 (s, 3 H), 0.97 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 207.8, 135.5, 134.9, 133.2, 133.0, 132.5, 132.4, 129.9, 129.8, 128.2, 127.9, 127.8, 127.7, 126.6, 126.1, 125.9, 125.7, 114.8, 106.7, 95.9, 80.9, 79.9, 73.4, 67.6, 28.7, 27.5, 26.8, 26.6, 19.1. ESI-MS m/z: [M þ Na]þ found 633.1, calcd 633.2751. A solution of lithium borohydride (122.0 mL of a 2 M solution in THF, 244 mmol) was added dropwise over 30 min to a cold (-78 °C) solution of the ketone (163 mmol) from above in methanol (500 mL). After the addition was complete, the cooling bath was removed, and the reaction was stirred for 2 h. The reaction was then cooled in an ice bath and carefully quenched using saturated NH4Cl solution and diluted with ethyl acetate. The organic layer was separated and sequentially washed with water, saturated sodium bicarbonate, and brine, dried (Na2SO4), and concentrated. Purification by column chromatography (silica gel, eluting with 30% ethyl acetate in hexanes) provided alcohol 36 (97.2 g, 95%, 36:35 > 15:1) as a viscous oil. General Procedure for Mesylation and Acetolysis of 1,2-Acetonide. Methanesulfonyl chloride (1.4 equiv) was added dropwise over 30 min to a cold (0 °C) solution of alcohol (1 equiv), triethylamine (1.8 equiv), and DMAP (0.14 equiv) in dichloromethane (0.5 M). After stirring for 3 to 6 h, the reaction was diluted with chloroform. The organic layer was sequentially washed with 5% HCl, saturated sodium bicarbonate, and brine, 1578

J. Org. Chem. Vol. 75, No. 5, 2010

Seth et al. dried (Na2SO4), and concentrated to provide the mesylate, which was used without any further purification. Concentrated sulfuric acid (6-10 drops) was added to a solution of crude mesylate (1 equiv) from above, acetic acid, and acetic anhydride (5:1, 0.3 M). After stirring for 3 h at rt, the solvent was removed under reduced pressure, and the residual oil was diluted with ethyl acetate. The organic layer was washed with water, saturated sodium bicarbonate (until pH >10), and brine, dried (Na2SO4), and concentrated. Purification by column chromatography (silica gel, eluting with 20% to 30% ethyl acetate in hexanes) provided an anomeric mixture of diacetates. 1,2-Di-O-acetyl-5-O-(tert-butyldiphenylsilyl)-4-C-(1-methanesulfonyloxy-2-methoxyethyl)-3-O-(2-naphthyl)-r-D-ribofuranose (37a,b). Prepared from alcohol 34a,b (11.0 g, 17.1 mmol) to provide an anomeric mixture of anomeric diacetates 37a,b (10.0 g, 77%) as a viscous oil. ESI-MS m/z: [M þ Na]þ found 787.2, calcd 787.2687. Anal. Calcd for C40H48O11SSi.1 H2O: C, 61.36; H, 6.44. Found: C, 61.08; H, 6.15. 1,2-Di-O-acetyl-5-O-(tert-butyldiphenylsilyl)-4-C-(1S-methanesulfonyloxyethyl)-3-O-(2-naphthyl)-r-D-ribofuranose (38). Prepared from alcohol 35 (7.4 g, 12.0 mmol) using the general procedure described above to provide anomeric diacetates 38 (7.7 g, 89%) as a viscous oil. 1H NMR for major anomer (300 MHz, CDCl3) δ: 7.84-7.35 (m, 17 H), 6.22 (s, 1 H), 5.37 (d, J = 5.3 Hz, 1 H), 5.34-5.22 (m, 1 H), 4.77-4.58 (m, 2 H), 4.42 (d, J = 5.5 Hz, 1 H), 3.83 (d, 1 H, J = 10.9 Hz), 3.74 (d, J = 10.9 Hz, 1 H), 2.79 (s, 3 H), 2.11 (s, 3 H), 1.78 (s, 3 H), 1.56 (d, J = 4.1 Hz, 3 H), 1.06 (s, 9 H). 13 C NMR for anomeric mixture (75 MHz, CDCl3) δ: 169.7, 169.0, 135.6, 134.4, 133.1, 133.0, 132.6, 130.0, 129.9, 128.4, 128.0, 127.9, 127.8, 127.7, 126.8, 126.3, 126.2, 125.5, 98.2, 88.2, 78.9, 78.8, 74.2, 74.1, 65.6, 38.8, 26.9, 20.9, 20.8, 19.4, 17.0. ESI-MS m/ z: [M þ Na]þ found 757.1, calcd 757.2581. 1,2-Di-O-acetyl-5-O-(tert-butyldiphenylsilyl)-4-C-(1R-methanesulfonyloxyethyl)-3-O-(2-naphthyl)-r-D-ribofuranose (39). Prepared from alcohol 36 (16.9 g, 27.6 mmol) using the general procedure described above to provide anomeric diacetates 39 (18.2 g, 90%) as a viscous oil. 1H NMR for major anomer (300 MHz, CDCl3) δ: 7.85-7.41 (m, 17 H), 6.21 (s, 1 H), 5.57-5.45 (m, 1 H), 5.36-5.23 (m, 1 H), 4.76 (d, J = 11.3 Hz, 1 H), 4.70 - 4.60 (m, 1H), 3.92-3.71 (m, 3 H), 3.01 (s, 3 H), 2.14 (s, 3 H), 1.78 (s, 3 H), 1.43 (d, J = 6.6 Hz, 3 H), 1.05 (s, 9 H). 13C NMR for anomeric mixture (75 MHz, CDCl3) δ: 170.6, 169.9, 169.4, 135.7, 135.6, 135.6, 135.5, 135.0, 134.1, 133.2, 132.8, 132.4, 132.2, 130.1, 130.0, 129.9, 128.5, 128.1, 127.9, 127.9, 127.8, 127.8, 127.7, 126.9, 126.4, 126.3, 125.8, 125.5, 125.1, 97.8, 94.1, 90.4, 88.2, 81.7, 81.1, 77.9, 77.7, 74.8, 74.5, 74.2, 73.2, 62.8, 38.6, 38.4, 26.8, 21.3, 20.8, 20.5, 19.3, 19.1, 18.3, 18.1. ESI-MS m/z: [M þ Na]þ found 757.1, calcd 757.2581. Anal. Calcd for C39H46O10SSi.0.25 H2O: C, 63.35; H, 6.33. Found: C, 63.32; H, 6.26. General Procedure for Vorbruggen Reaction and Ring Closure. N,O-Bis(trimethylsilyl)acetamide (4 equiv) was added to a suspension of anomeric diacetates (1 equiv) and uracil (2 equiv) in acetonitrile (0.3M). After heating at 40 °C for 15 min to get a clear solution, the reaction was cooled in an ice bath and trimethylsilyltriflate (1.5 equiv) was added. After refluxing for 2 h the reaction was cooled to room temperature and poured into ethyl acetate. The organic layer was washed with half-saturated sodium bicarbonate solution and brine, dried (Na2SO4), and concentrated to provide the corresponding nucleoside mixture, which was used without any further purification. Potassium carbonate (3 equiv) was added to a solution of crude nucleoside from above in methanol (0.1 M). After stirring at room temperature for 16 h, the reaction was concentrated under reduced pressure. The residue was dissolved in ethyl acetate, and the organic layer was washed with water and brine, dried (Na2SO4), and concentrated. Purification by column chromatography (silica gel, eluting with 5% to 7.5% acetone in chloroform) provided the cyclized nucleoside.

Seth et al. (1S,3R,4R,6R,7S)-1-(tert-Butyldiphenylsilyloxymethyl)-6-methoxymethyl-7-(2-naphthyloxy)-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane and (1S,3R,4R,6S,7S)-1-(tert-Butyldiphenylsilyloxymethyl)6-methoxymethyl-7-(2-naphthyloxy)-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (40a,b). Prepared from diacetates 37a,b (10.0 g, 13.0 mmol) using the general procedure described above to provide nucleosides 40a,b (7.8 g, 89% from 36a,b) as a white solid. 1H NMR (300 MHz, CDCl3) δ: 8.58 (br s, 2 H), 7.94-7.27 (m, 36 H), 5.70-5.58 (m, 2 H), 5.48-5.31 (m, 2 H), 4.94-4.58 (m, 5 H), 4.50 (s, 1 H), 4.35-4.26 (m, 1 H), 4.24 (s, 1 H), 4.16-3.92 (m, 8 H), 3.61-3.47 (m, 5 H), 3.26 (s, 3 H), 3.18 (s, 3 H), 1.07 (s, 18 H). 13C NMR (75 MHz, CDCl3) δ: 162.8, 149.6, 149.5, 139.1, 139.0, 135.6, 135.5, 135.3, 134.0, 133.8, 133.2, 132.7, 132.2, 130.1, 130.1, 128.5, 128.5, 128.0, 127.9, 127.8, 127.8, 127.1, 126.8, 126.5, 126.4, 126.3, 125.7, 125.6, 101.7, 101.6, 89.2, 89.1, 86.9, 86.7, 82.9, 78.6, 77.2, 76.7, 76.3, 75.9, 72.7, 72.6, 71.0, 70.1, 59.3, 58.9, 58.5, 26.8, 19.3. ESI-MS m/z: [M þ H]þ found 679.2, calcd 679.2761. (1S,3R,4R,6R,7S)-1-(tert-Butyldiphenylsilyloxymethyl)-6-methyl7-(2-naphthyloxy)-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (41). Prepared from anomeric diacetates 38 (7.5 g, 10.2 mmol) using the general procedure to provide nucleoside 41 (5.3 g, 81%) as a white solid. 1H NMR (300 MHz, CDCl3) δ: 8.74 (br s, 1 H), 7.91 (d, J = 8.3 Hz, 1 H), 7.87-7.28 (m, 17 H), 5.65 (s, 1 H), 5.43 (d, J = 8.1 Hz, 1 H), 4.83 (d, J = 11.5 Hz, 1 H), 4.75 (d, J = 11.5 Hz, 1 H), 4.49 (s, 1H), 4.38-4.27 (m, 1 H), 4.20 (s, 1 H), 3.93-3.88 (m, 2 H), 1.19 (d, J = 6.4 Hz, 3 H), 1.07 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 162.9, 149.6, 139.2, 135.6, 135.3, 134.1, 133.2, 132.5, 132.0, 130.2, 130.1, 128.5, 128.0, 127.9, 127.8, 126.9, 126.4, 126.3, 125.7, 101.6, 88.8, 86.7, 76.5, 76.3, 72.6, 58.4, 26.8, 19.3, 13.8. HRMS (ESI-FT), Calcd for C38H41N2O6Si 649.2728; found 649.2738. ESI-MS m/z: [M þ H]þ found 649.2. Anal. Calcd for C38H40N2O6Si.0.5 H2O: C, 69.38; H, 6.28; N, 4.26. Found: C, 69.01; H, 6.19; N, 4.26. (1S,3R,4R,6S,7S)-1-(tert-Butyldiphenylsilyloxymethyl)-6-methyl7-(2-naphthyloxy)-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (42). Prepared from anomeric diacetates 39 (12.3 g, 16.7 mmol) using the general procedure to provide nucleoside 42 (9.2 g, 85%) as a white solid. 1H NMR (300 MHz, CDCl3) δ: 9.20 (br s, 1 H), 7.84-7.31 (m, 18 H), 5.66 (s, 1 H), 5.43 (d, J = 7.9 Hz, 1 H), 4.82 (d, J = 11.3 Hz, 1 H), 4.72 (s, 1H), 4.71-4.61 (m, 1 H), 4.14-3.97 (m, 4 H), 1.26 (d, J = 6.6 Hz, 3 H), 1.07 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 163.2, 149.7, 139.1, 135.5, 135.3, 134.0, 133.1, 132.6, 132.1, 130.1, 130.0, 128.4, 127.9, 127.8, 127.7, 126.9, 126.4, 126.3, 125.7, 101.5, 89.3, 87.1, 81.1, 76.7, 76.5, 72.6, 58.7, 26.7, 19.3, 16.3. ESI-MS m/z: [M þ H]þ found 649.2, calcd 649.2656. Anal. Calcd for C38H40N2O6Si.0.25 H2O: C, 69.86; H, 6.25; N, 4.29. Found: C, 69.61; H, 6.17; N, 4.22. General Procedure for Deprotection of 30 O-Nap Group Using 2,3-Dichloro-4,5-dicyano Quinone (DDQ). DDQ (2-2.5 equiv) was added to a solution of nucleoside (1 equiv) in dichloromethane and water (20:1, 0.1 M). The biphasic reaction was stirred at room temperature for 16 h, after which the solvent was evaporated under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic layer was sequentially washed with sodium bisulfite, saturated sodium bicarbonate, and brine, dried (Na2SO4), and concentrated. Purification by column chromatography (silica gel, eluting 10% to 30% acetone in chloroform) provided the 30 OH nucleoside. (1S,3R,4R,6R,7S)-1-(tert-Butyldiphenylsilyloxymethyl)-7-hydroxy-6-methoxymethyl-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (43a) and (1S,3R,4R,6S,7S)-1-(tert-Butyldiphenylsilyloxymethyl)-7hydroxy-6-methoxymethyl-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (43b). Prepared from nucleosides 40a,b (16.8 g, 24.9 mmol) using the general procedure to provide nucleosides 43a (6.4 g, 50%, Rf = 0.15, 25% acetone in chloroform) and 43b (6.7 g, 48%, Rf = 0.22, 25% acetone in chloroform) as crisp foams, respectively. 43a: 1H NMR (300 MHz, CDCl3) δ: 9.44 (s, 1 H), 7.91 (d, J = 8.3 Hz, 1 H), 7.77-7.64 (m, 4 H), 7.54-7.35 (m, 6 H), 5.58 (s, 1

JOC Article H), 5.52 (d, J = 8.3 Hz, 1 H), 4.40 (s, 1 H), 4.32 (d, J = 5.1 Hz, 1 H), 4.18 (t, J = 6.3 Hz, 1 H), 4.07 (d, J = 12.2 Hz, 1 H), 3.95 (d, J = 12.4, 1 H), 3.56 (d, J = 6.4 Hz, 2 H), 3.27 (s, 3 H), 3.21-3.13 (m, 1 H), 1.09 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 163.5, 149.9, 139.2, 135.6, 135.4, 132.7, 132.3, 130.2, 130.1, 128.0, 101.7, 89.2, 86.4, 79.0, 77.9, 71.2, 70.4, 59.2, 58.4, 26.8, 19.3. HRMS (ESI-FT) Calcd for C28H35N2O7Si, 539.2208; Found 539.2206. ESI-MS m/z: [M þ Na]þ found 539.2. 43b: 1H NMR (300 MHz, CDCl3) δ: 9.20 (br s, 1 H), 7.81-7.61 (m, 4 H), 7.65 (d, J = 8.1 Hz, 1H) 7.55-7.35 (m, 6 H), 5.64 (s, 1 H), 5.60 (d, J = 8.1 Hz, 1 H), 5.07 (d, J = 10.7 Hz, 1 H), 4.43 (s, 1 H), 4.18-3.94 (m, 4 H), 3.66 (dd, J = 11.5, 2.8 Hz, 1 H), 3.52 (d, J = 11.3 Hz, 1 H), 3.35 (s, 3 H), 1.09 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 163.2, 149.7, 139.0, 135.8, 135.4, 132.7, 132.1, 130.1, 130.1, 128.0, 127.9, 101.8, 90.1, 86.4, 82.8, 80.3, 70.5, 70.1, 59.5, 59.2, 26.7, 19.3. HRMS (ESI-FT) Calcd for C28H35N2O7Si, 539.2208; Found 539.2209. ESI-MS m/z: [M þ Na]þ found 539.2. (1S,3R,4R,6R,7S)-1-(tert-Butyldiphenylsilyloxymethyl)-7-hydroxy-6-methyl-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (44). Prepared from nucleoside 41 (5.3 g, 8.2 mmol) using the general procedure to provide nucleoside 44 (4.15 g, 99%) as a crisp foam. 1 H NMR (300 MHz, CDCl3) δ: 9.31 (br s, 1 H), 7.92 (d, J = 8.1 Hz, 1 H), 7.77-7.64 (m, 4 H), 7.54-7.35 (m, 6 H), 5.60 (s, 1 H), 5.53 (d, J = 8.1 Hz, 1 H), 4.35 (s, 1 H), 4.30 (d, J = 5.1 Hz, 1 H), 4.25-4.16 (m, 1 H), 3.93-3.86 (m, 2 H), 2.91 (m, 1 H), 1.20 (d, J = 6.2 Hz, 3 H), 1.09 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 163.4, 149.8, 139.2, 135.6, 135.4, 132.5, 132.2, 130.2, 130.1, 128.0, 101.7, 88.9, 86.3, 79.0, 75.8, 71.3, 58.4, 26.8, 19.3, 13.9. ESI-MS m/z: [M þ H]þ found 509.1, calcd 509.2030. (1S,3R,4R,6S,7S)-1-(tert-Butyldiphenylsilyloxymethyl)-7-hydroxy-6-methyl-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (45). Prepared from nucleoside 42 (9.2 g, 14.2 mmol) using the general procedure to provide nucleoside 45 (6.2 g, 86%) as a crisp foam. 1H NMR (300 MHz, CDCl3) δ: 9.67 (br s, 1 H), 7.80-7.65 (m, 5 H), 7.52-7.36 (m, 6 H), 5.59 (s, 1 H), 5.49 (d, J = 8.1 Hz, 1 H), 4.56 (s, 1 H), 4.22-3.96 (m, 4 H), 3.13 (m, 1 H), 1.28 (d, J = 6.8 Hz, 3 H), 1.09 (s, 9 H). 13C NMR (75 MHz, CDCl3) δ: 163.7, 149.9, 139.3, 135.6, 135.4, 132.7, 132.3, 130.1, 130.1, 128.0, 101.6, 89.4, 86.7, 81.1, 79.7, 70.8, 58.9, 26.8, 19.3, 16.3. ESI-MS m/z: [M þ H]þ found 509.1, calcd 509.2030. General Procedure for Removing 50 O-TBDPS Protecting Group. Triethylamine trihydrofluoride (6 equiv) was added to a solution of nucleoside (1 equiv) and triethylamine (2.5 equiv) in THF (0.1 M), and the reaction was stirred at rt for 1-2 days. The solvent was removed under reduced pressure, and the thick oil was purified by chromatography (silica gel, eluting with 5% to 12.5% methanol in chloroform) provided the corresponding deprotected nucleoside. (1S,3R,4R,6R,7S)-7-Hydroxy-1-hydroxymethyl-6-methoxymethyl-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (46). Prepared from nucleoside 43a (6.7 g, 12.0 mmol) using the general procedure described above to provide 46 (3.7 g, 99%). 1H NMR (300 MHz, DMSO-d6) δ: 11.36 (s, 1 H), 7.79 (d, J = 8.1 Hz, 1 H), 5.73 (d, J = 4.1 Hz, 1H), 5.64 (d, J = 8.1 Hz, 1 H), 5.40 (s, 1 H), 5.20 (br s, 1 H), 4.10 (s, 1H), 4.02-3.94 (m, 2 H), 3.75 (d, J = 3.8 Hz, 1 H), 3.71-3.54 (m, 2 H), 3.46 (dd, J = 6.4 Hz, 10.0, 1 H), 3.28 (s, 3 H). 13C NMR (75 MHz, DMSO-d6) δ: 163.2, 149.9, 139.0, 100.8, 88.8, 85.8, 78.6, 77.6, 70.5, 69.8, 58.5, 55.2. ESI-MS m/z: [M þ H]þ found 301.1, calcd 301.0958. Anal. Calcd for C12H16N2O7.0.11 CHCl3: C, 46.39; H, 5.18; N, 8.93. Found: C, 46.17; H, 5.22; N, 8.77. (1S,3R,4R,6S,7S)-7-Hydroxy-1-hydroxymethyl-6-methoxymethyl-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (47). Prepared from nucleoside 43b (6.4 g, 12.5 mmol) using the general procedure described above to provide 47 (3.5 g, 99%). 1H NMR (300 MHz, DMSO-d6) δ: 11.42 (br s, 1 H), 7.80 (d, J = 8.1 Hz, 1 H), 5.73 (br s, 1 H), 5.68 (d, J = 8.1 Hz, 1 H), 5.47 (s, 1 J. Org. Chem. Vol. 75, No. 5, 2010

1579

JOC Article H), 5.22 (br s, 1 H), 4.28 (s, 1 H), 4.02-3.91 (m, 2 H), 3.83 (br s, 2 H), 3.59 (d, J = 5.5 Hz, 2 H), 3.30 (s, 3 H). 13C NMR (75 MHz, DMSO-d6) δ: 163.3, 150.0, 139.2, 100.8, 89.0, 86.1, 82.8, 79.2, 71.0, 68.9, 58.2, 55.8. ESI-MS m/z: [M þ H]þ found 301.1, calcd 301.0958. (1S,3R,4R,6R,7S)-7-Hydroxy-1-hydroxymethyl-6-methyl3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (48). Prepared from nucleoside 44 (4.2 g, 8.2 mmol) using the general procedure described above to provide 48 (2.1 g, 92%). 1H NMR (300 MHz, DMSO-d6) δ: 11.35 (br s, 1 H), 7.81 (d, J = 8.1 Hz, 1 H), 5.71-5.59 (m, 2 H), 5.38 (s, 1 H), 5.16 (t, J = 5.3 Hz, 1 H), 4.21-4.06 (m, 1 H), 4.05 (s, 1H), 3.99 (d, J = 4.1 Hz, 1 H), 3.62 (d, J = 5.1 Hz, 2 H), 1.14 (d, 3 H). 13C NMR (75 MHz, DMSO-d6) δ: 163.1, 149.8, 138.9, 100.6, 88.4, 85.6, 78.4, 75.0, 69.7, 55.1, 13.8. ESI-MS m/z: [M þ H]þ found 271.0, calcd 271.0872. Anal. Calcd for C11H14N2O6.0.5 H2O: C, 47.31; H, 5.41; N, 10.03. Found: C, 47.01; H, 5.29; N, 9.70. (1S,3R,4R,6S,7S)-7-Hydroxy-1-hydroxymethyl-6-methyl3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (49). Prepared from nucleoside 45 (6.2 g, 12.2 mmol) using the general procedure described above to provide 49 (3.3 g, 99%). 1H NMR (300 MHz, DMSO-d6) δ: 11.36 (s, 1 H), 7.73 (d, J = 8.1 Hz, 1 H), 5.62 (d, J = 8.1 Hz, 1 H), 5.55 (d, J = 3.8 Hz, 1 H), 5.38 (s, 1 H), 5.11 (t, J = 5.4 Hz, 1 H), 4.19 (s, 1 H), 3.94 (m, 1 H), 3.86 (d, J = 3.8 Hz, 1 H), 3.80 (d, J = 5.3 Hz, 2 H), 1.22 (d, 3 H). 13C NMR (75 MHz, DMSO-d6) δ: 163.1, 149.9, 139.2, 100.7, 89.0, 86.1, 80.2, 79.2, 69.6, 55.9, 16.2. HRMS (ESI-FT), Calcd for C11H14N2O6Na, 293.0744; Found 293.0745. ESI-MS m/z: [M þ H]þ found 271.0. Anal. Calcd for C11H14N2O6.0.25 CH3OH: C, 48.56; H, 5.43; N, 10.07. Found: C, 48.71; H, 5.06; N, 9.92. General Procedure for 50 O-DMT Protection. 4,40 -Dimethoxytrityl chloride (1.5 equiv) was added to a solution of nucleoside (1 equiv) in pyridine (0.2 M). After stirring at rt for 16 h, the reaction was quenched with methanol and diluted with ethyl acetate. The organic layer was washed with water and brine, dried (Na2SO4), and concentrated. Purification by chromatography (silica gel, eluting with 10% to 20% acetone in dichloromethane) provided the corresponding 50 O-DMTprotected nucleoside. (1S,3R,4R,6R,7S)-1-(4,40 -Dimethoxytrityloxymethyl)-7-hydroxy-6-methoxymethyl-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (50). Prepared from nucleoside 46 (3.7 g, 12.5 mmol) using the general procedure described above to provide 50 (6.7 g, 90%). 1H NMR (300 MHz, CDCl3) δ: 9.11 (br s, 1 H), 8.01 (d, J = 8.1 Hz, 1 H), 7.45-7.24 (m, 9 H), 6.86 (d, J = 8.5 Hz, 4 H), 5.66-5.51 (m, 2 H), 4.46-4.31 (m, 2 H), 4.23-4.08 (m, 1 H), 3.79 (s, 6 H), 3.70-3.40 (m, 4 H), 3.24 (s, 3 H), 2.69 (d, J = 4.7 Hz, 1 H). 13C NMR (75 MHz, CDCl3) δ: 163.3, 158.7, 149.7, 144.4, 139.4, 135.3, 130.1, 130.0, 128.0, 127.2, 113.3, 101.8, 88.2, 87.0, 86.4, 78.9, 78.2, 71.6, 70.3, 59.2, 57.4, 55.3. ESI-MS m/z: [M þ Na]þ found 625.1, calcd 625.2264. (1S,3R,4R,6S,7S)-1-(4,40 -Dimethoxytrityloxymethyl)-7-hydroxy-6-methoxymethyl-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (51). Prepared from nucleoside 47 (3.5 g, 12.0 mmol) using the general procedure described above to provide 51 (6.5 g, 91%). 1H NMR (300 MHz, CDCl3) δ: 8.69 (br s, 1 H), 7.70 (d, J = 8.3 Hz, 1 H), 7.50-7.24 (m, 9 H), 6.86 (d, J = 8.7 Hz, 4 H), 5.75-5.60 (m, 2 H), 5.05 (d, J = 10.9 Hz, 1 H), 4.43 (s, 1 H), 4.17 (s, 1 H), 3.97 (d, J = 10.9 Hz, 1 H), 3.80 (s, 6 H), 3.75-3.58 (m, 2 H), 3.41 (m, 2 H), 3.22 (s, 3 H). 13C NMR (75 MHz, CDCl3) δ: 162.8, 158.7, 149.6, 144.3, 138.9, 135.5, 135.1, 130.0, 128.0, 128.0, 127.1, 113.3, 113.3, 101.9, 89.2, 86.6, 86.6, 83.1, 80.3, 71.1, 70.0, 59.2, 58.9, 55.3. ESI-MS m/z: [M þ Na]þ found 625.1, calcd 625.2264. (1S,3R,4R,6R,7S)-1-(4,40 -Dimethoxytrityloxymethyl)-7-hydroxy-6-methyl-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (52). Prepared from nucleoside 48 (2.1 g, 7.5 mmol) using the general procedure described above to provide 52 (4.3 g, 99%). 1H NMR 1580

J. Org. Chem. Vol. 75, No. 5, 2010

Seth et al. (300 MHz, CDCl3) δ: 9.03 (br s, 1 H), 8.03 (d, J = 8.1 Hz, 1 H), 7.47-7.25 (m, 9 H), 6.94-6.76 (m, 4 H), 5.69-5.52 (m, 2 H), 4.42-4.27 (m, 2 H), 4.16 (m, 1 H), 3.80 (s, 6 H), 3.51-3.34 (m, 2 H), 2.49 (d, J = 5.7 Hz, 1 H), 1.17 (d, 3 H). 13C NMR (75 MHz, CDCl3) δ: 163.3, 158.8, 149.7, 144.4, 139.4, 135.2, 135.2, 130.0, 130.0, 128.0, 128.0, 127.2, 113.3, 101.7, 88.1, 87.0, 86.4, 78.9, 76.0, 71.7, 60.4, 57.5, 55.3, 13.8. 293.0745. HRMS (ESI-FT): calcd for C32H32N2O8Na 595.2051; found 595.2048. ESI-MS m/z: [M þ Na]þ found 595.1. (1S,3R,4R,6S,7S)-1-(4,40 -Dimethoxytrityloxymethyl)-7-hydroxy-6-methyl-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (53). Prepared from nucleoside 49 (3.3 g, 12.2 mmol) using the general procedure described above to provide 53 (7.0 g, 99%). 1H NMR (300 MHz, CDCl3) δ: 9.53-9.17 (br s, 1 H), 7.86 (d, J = 8.1 Hz, 1 H), 7.50-7.26 (m, 9 H), 6.85 (d, J = 8.7 Hz, 4 H), 5.69-5.56 (m, 2 H), 4.58 (s, 1 H), 4.22 (d, J = 5.3 Hz, 1 H), 4.19-4.07 (m, 1 H), 3.78 (s, 6 H), 3.58 (d, J = 10.9 Hz, 1 H), 3.53 (d, J = 11.1 Hz, 1 H), 1.18 (d, J = 6.8 Hz, 3 H). 13C NMR (75 MHz, CDCl3) δ: 163.5, 158.7, 149.8, 144.5, 139.4, 135.4, 135.2, 130.1, 130.0, 128.0, 127.1, 113.3, 113.2, 101.8, 88.5, 86.8, 86.8, 81.2, 79.6, 71.3, 58.2, 55.2, 16.4. HRMS (ESI-FT): calcd for C32H32N2O8Na 595.2051; found 595.2050. ESI-MS m/z: [M þ Na]þ found 595.1. General Procedure for Uridine Phosphoramidite Synthesis. 2-Cyanoethyl tetraisopropylphosphordiamidite (1.5 equiv) was added to a solution of nucleoside (1 equiv), tetrazole (0.8 equiv), and N-methylimidazole (0.25 equiv) in DMF (0.2 M). After stirring at room temperature for 8 h the reaction was diluted EtOAc, and the organic layer was washed with brine, dried (Na2SO4), and concentrated. Purification by chromatography (silica gel, eluting with 50% to 60% ethyl acetate in hexanes) provided the corresponding phosphoramidite as a white foam. (1S,3R,4R,6R,7S)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,40 -dimethoxytrityloxymethyl)-6-methoxymethyl3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (54). Prepared from nucleoside 50 (2.0 g, 3.3 mmol) using the general procedure described above to provide 54 (2.54 g, 96%). 31P NMR (121 MHz, CDCl3) δ: 149.8, 149.5. HRMS (ESI-FT): calcd for C42H52N4O10P 803.3416; found 803.3421. ESI-MS m/z: [M þ H]þ found 803.1. Anal. Calcd for C42H51N4O10P.0.25 H2O: C, 62.48; H, 6.43; N, 6.94. Found: C, 62.55; H, 6.21; N, 6.85. (1S,3R,4R,6S,7S)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,40 -dimethoxytrityloxymethyl)-6-methoxymethyl3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (55). Prepared from nucleoside 51 (2.0 g, 3.3 mmol) using the general procedure described above to provide 55 (2.55 g, 96%). 31P NMR (121 MHz, CDCl3) δ: 150.0, 149.8. HRMS (ESI-FT): calcd for C42H52N4O10P 803.3416; found 803.3426. ESI-MS m/z: [M þ H]þ found 803.2. Anal. Calcd for C42H51N4O10P.0.5 H2O: C, 62.13; H, 6.46; N, 6.90. Found: C, 62.46; H, 6.18; N, 6.72. (1S,3R,4R,6R,7S)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,40 -dimethoxytrityloxymethyl)-6-methyl-3-(uracil1-yl)-2,5-dioxabicyclo[2.2.1]heptane (56). Prepared from nucleoside 52 (2.1 g, 3.7 mmol) using the general procedure described above to provide 56 (2.7 g, 96%). 31P NMR (121 MHz, CDCl3) δ: 149.8, 149.2. HRMS (ESI-FT): calcd for C41H50N4O9P 773.3310; found 773.3314. ESI-MS m/z: [M þ H]þ found 773.2. Anal. Calcd for C41H49N4O9P.0.25 H2O: C, 63.35; H, 6.42; N, 7.21. Found: C, 63.02; H, 6.37; N, 7.06. (1S,3R,4R,6S,7S)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,40 -dimethoxytrityloxymethyl)-6-methyl-3-(uracil1-yl)-2,5-dioxabicyclo[2.2.1]heptane (57). Prepared from nucleoside 53 (3.0 g, 5.2 mmol) using the general procedure described above to provide 57 (3.4 g, 83%). 31P NMR (121 MHz, CDCl3) δ: 149.6, 149.4. HRMS (ESI-FT): calcd for C41H50N4O9P 773.3310; found 773.3315. ESI-MS m/z: [M þ H]þ found 773.2. Anal. Calcd for C41H49N4O9P.0.5 H2O: C, 62.99; H, 6.45; N, 7.17. Found: C, 62.77; H, 6.60; N, 7.06.

Seth et al.

Acknowledgment. The authors thank Prof. Michael Jung for many useful suggestions. Supporting Information Available: General experimental procedures for synthesis of 58-76; 1H and 13C NMR spectra and analytical data for all new compounds; 31P NMR spectra

JOC Article for all phosphoramidites; protocols for oligonucleotide synthesis and purification, thermal denaturation, and nuclease stability experiments; analytical data for oligonucleotides and X-ray crystal structure and CIF file for 49. This material is available free of charge via the Internet at http:// pubs.acs.org.

J. Org. Chem. Vol. 75, No. 5, 2010

1581